About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers.
Company Information
| Established: | 1997 |
| Headquarters: | Novato, California USA |
| Stock Symbol: | NASDAQ: BMRN |
| Stock Quote: |  More  |
2010 Highlights
| Total Revenue: | $376.3 Million |
| Employees: | >800 worldwide |
| Clinical Research: | Conducted internationally |
| Products: | KUVAN® for PKU, Naglazyme® for MPS VI, Aldurazyme® for MPS I, Firdapse™ (currently approved in the EU only) for LEMS |
| Commercial Operations: | Over 40 countries |
| Clinical Pipeline: | GALNS for MPS IVA, PEG-PAL for PKU, BMN 701 for Pompe disease, BMN 673 for genetically-defined cancers |
| Focus: | Rare (Orphan) genetic diseases |
| Strategy: | Providing rapid access to treatment for patients with serious unmet medical needs, optimizing powerful biology with demonstrated potential and development clarity, accelerating approval process, strategic pipeline development |
Products
BioMarin has developed and commercialized four products since 1997, a remarkable
accomplishment in the biopharmaceutical industry, and a testament to the company’s
passion and dedication to patients with serious unmet medical needs. For complete
safety and prescribing information, including a boxed warning for Aldurazyme,
please visit www.kuvan.com, www.naglazyme.com and www.aldurazyme.com.
